CELATOR PHARMACEUTICALS
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
CELATOR PHARMACEUTICALS
Social Links:
Industry:
Biopharma Biotechnology Health Care Health Diagnostics Medical Pharmaceutical
Founded:
1999-01-01
Address:
Princeton, New Jersey, United States
Country:
United States
Website Url:
http://www.celatorpharma.com
Total Employee:
11+
Status:
Active
Contact:
(609) 243-0123
Email Addresses:
[email protected]
Total Funding:
131.88 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Wix Hosted Proofpoint CSC Global DNS
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Debt Financing - Celator Pharmaceuticals
ROTH Capital Partners
ROTH Capital Partners investment in Private Equity Round - Celator Pharmaceuticals
Valence Life Sciences
Valence Life Sciences investment in Private Equity Round - Celator Pharmaceuticals
Ventures West
Ventures West investment in Series D - Celator Pharmaceuticals
TL Ventures
TL Ventures investment in Series D - Celator Pharmaceuticals
Quaker BioVentures
Quaker BioVentures investment in Series D - Celator Pharmaceuticals
Domain Associates
Domain Associates investment in Series D - Celator Pharmaceuticals
GrowthWorks Capital
GrowthWorks Capital investment in Series D - Celator Pharmaceuticals
BDC Venture Capital
BDC Venture Capital investment in Series D - Celator Pharmaceuticals
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Series D - Celator Pharmaceuticals
Official Site Inspections
http://www.celatorpharma.com
- Host name: 165.160.13.20
- IP address: 165.160.13.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Celator Pharmaceuticals"
Celator Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Celator Pharmaceuticals, Inc. of Ewing, NJ. Get the latest business insights from Dun & Bradstreet.See details»
Celator Pharmaceuticals Inc. | BDC.ca
Celator is a biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the …See details»
Celator Pharmaceuticals - PitchBook
Celator Pharmaceuticals General Information Description. Operator of a pharmaceutical company intended to improve clinical outcomes. The company focuses on CombiPlex, a drug ratio technology platform that enables the …See details»
Celator Pharmaceuticals - Ownership and Business Overview
May 31, 2016 www.celatorpharma.com. Profile Investors (1) Analytics Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company that is transforming the science of …See details»
Celator (CPXX): A Unique Drug Ratio Technology Company for …
May 28, 2014 By Grant Zeng, CFA NASDAQ:CPXX Overview Celator Pharmaceuticals is a late stage development pharmaceutical company focused on developing new and more effective …See details»
Celator: A Unique Drug Ratio Technology Company For …
Jul 23, 2014 Company Overview. Celator Pharmaceuticals (NASDAQ:CPXX) is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various cancers.See details»
Celator(R) Pharmaceuticals Announces Positive Data From Phase 2 …
May 3, 2010 For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov . …See details»
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce …
May 31, 2016 For more information, please visit Celator's website at www.celatorpharma.com. About VYXEOS VYXEOS (cytarabine:daunorubicin) Liposome for Injection, also known as …See details»
Celator® Pharmaceuticals Appoints Jean-Pierre Bizzari to Board of …
EWING, N.J., March 2, 2015 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and …See details»
Jazz Pharmaceuticals to acquire Celator Pharmaceuticals for …
May 31, 2016 Information you can trust. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide …See details»
Jazz Pharmaceuticals to Acquire Celator Pharmaceuticals for …
May 31, 2016 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that they have entered into a definitive agreement for Jazz …See details»
Celator Pharmaceuticals, Inc. | Insights
Aug 5, 2017 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Celator Pharmaceuticals Inc.'s CEO Scott Jackson and President …
Apr 22, 2015 Celator Pharmaceuticals Inc.'s remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, …See details»
Jazz Pharma to buy Celator in $1.5 billion deal | Reuters
May 31, 2016 Ireland-based Jazz Pharmaceuticals Plc <JAZZ.O> will buy U.S.-based Celator Pharmaceuticals Inc <CPXX.O> in a cash deal valued at about $1.5 billion (1.02 billion …See details»
Celator® Pharmaceuticals Presents Positive Data from Phase 2 …
Dec 8, 2010 For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov. …See details»
Jazz Pharma snaps up leukemia drug with $1.5 billion deal for …
May 31, 2016 Dive Brief: Irish drug company Jazz Pharmaceuticals reached a deal to buy Ewing, New Jersey-based Celator Pharmaceuticals for $1.5 billion, gaining access to an …See details»
Celator® Pharmaceuticals Receives EMA Orphan Drug Status for …
Jan 26, 2012 PRINCETON, N.J.--(BUSINESS WIRE)-- Celator Pharmaceuticals today announced that the European Commission (EC) has granted orphan drug status to CPX-351, …See details»
Celator® Pharmaceuticals Completes Enrollment in a Second …
Oct 26, 2010 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of...See details»
Celator Pharmaceuticals® Announces VYXEOSâ„¢ Granted …
EWING, N.J., May 19, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that the United States Food and Drug Administration (FDA) granted …See details»